Detalhe da pesquisa
1.
Comparable Efficacy Between Ongoing Versus Initiation of Antiviral Therapy at Treatment for HBV-related Hepatocellular Carcinoma.
Clin Gastroenterol Hepatol
; 20(8): 1877-1880.e3, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35181566
2.
Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis.
BMC Gastroenterol
; 22(1): 135, 2022 Mar 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35337274
3.
Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Dig Dis Sci
; 67(10): 4939-4949, 2022 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35048224
4.
Correlation between Results of Semi-Quantitative and Quantitative Tests for Hepatitis B Virus Surface Antigen among Patients Achieving Viral Suppression with Antiviral Treatment.
Diagnostics (Basel)
; 12(7)2022 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-35885659
5.
Long-Term Outcomes of Transarterial Radioembolization for Large Single Hepatocellular Carcinoma: A Comparison to Resection.
J Nucl Med
; 63(8): 1215-1222, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34887340
6.
Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study.
J Hepatocell Carcinoma
; 8: 1565-1577, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34909425
7.
Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma.
Cancers (Basel)
; 13(23)2021 Nov 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34885118